Softwr

Research · head to head

Greenphire vs Schrodinger

Greenphire logo

Greenphire

Research

Clinical trial participant payments, reimbursement and travel, now part of Suvoda

From
On request
Rated
-
Full reviewWebsite
Schrodinger logo

Schrodinger

Research

Physics based molecular modelling and drug discovery software, licensed by token pool

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Greenphire the standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.; Schrodinger licences are sold as token pools rather than unlimited module access, so a department can be blocked mid campaign because colleagues are consuming concurrency, and expanding the pool is a new commercial negotiation rather than a setting.
  • They diverge on capability: Greenphire covers ClinCard, Schrodinger covers Maestro.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Greenphire and Schrodinger actually diverge.

Attributes where Greenphire and Schrodinger differ
AttributeGreenphireSchrodinger
PlatformsWeb, iOS, AndroidLinux, macOS, Windows, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Greenphire

  • ClinCard
  • Direct to bank payment
  • Expense reimbursement
  • Travel and logistics
  • Site payments
  • Budgeting and benchmarking
  • Tax handling

Only in Schrodinger

  • Maestro
  • Glide
  • FEP+
  • Desmond
  • Jaguar
  • LiveDesign
  • Materials Science suite

What people use each for

The jobs each tool is most often brought in to do.

Greenphire

  • A global Phase III trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payablenot Schrodinger
  • A decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodationnot Schrodinger
  • A trial in a population where slow reimbursement drives dropout and same day payment materially helps retentionnot Schrodinger
  • A sponsor that wants site payment milestones and participant payments handled by one vendor rather than twonot Schrodinger

Schrodinger

  • A medicinal chemistry programme using FEP+ to prioritise which analogues to synthesise, where avoiding a handful of wasted syntheses pays for the licencenot Greenphire
  • A structure based design campaign that needs docking at scale against a target with a good crystal structurenot Greenphire
  • A materials group modelling polymer or electrolyte properties before committing to formulation experimentsnot Greenphire
  • A university modelling group that qualifies for the published academic site licence and needs Maestro across a teaching and research cohortnot Greenphire

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Greenphire

  • The standalone greenphire.com site now redirects to Suvoda and the brands have been integrated, so buyers are contracting with a randomisation and supply vendor and should expect cross selling rather than an independent payments specialist.
  • Nothing is published on price, and the typical shape of a platform fee plus per participant and per transaction charges means the cost of a trial is not knowable until enrolment is known.
  • Payment method availability varies sharply by country, so a global protocol may end up with card payments in some regions and slow manual processes in others, which undermines the retention argument that justified the purchase.
  • Sites bear the administrative work of enrolling participants and triggering payments but are not the buyer, so adoption depends on the sponsor mandating it and site resistance is a real implementation risk.
  • Participant payments create tax reporting obligations that differ per jurisdiction, and the tooling helps but does not remove sponsor liability, so legal and finance review is required in every country the trial runs in.

Schrodinger

  • Licences are sold as token pools rather than unlimited module access, so a department can be blocked mid campaign because colleagues are consuming concurrency, and expanding the pool is a new commercial negotiation rather than a setting.
  • Commercial pricing is not published and is negotiated against modules, cores and term, so two companies of similar size can pay very different amounts and neither can benchmark the other.
  • FEP+ needs substantial GPU capacity that is not included in the licence, so the real annual cost includes cloud or on premise hardware that often rivals the software line item.
  • The tools require trained computational chemists to produce trustworthy results, and an organisation without that function will generate predictions it cannot interpret or defend to its own medicinal chemists.
  • Schrodinger runs its own internal drug discovery pipeline alongside selling software to discovery companies, and some prospective customers treat that dual role as a conflict when discussing proprietary targets, which slows procurement even where contractual separation exists.

Pricing, plan by plan

Greenphire

On request
  • Greenphire Patient Payments$undefined/year
    • Priced per study through a sales process
    • Typically a platform fee plus per participant and per transaction charges
    • Funding of the payment float is separate from the software fee

Schrodinger

On request
  • Commercial licence$undefined/year
    • Quoted per customer against modules, cores and licence term
    • Applications draw from a shared token pool that caps concurrency
    • GPU compute for FEP+ and Desmond is a separate cost, on premise or cloud
  • Academic site licence$undefined/year
    • Published academic entry around 7,500 USD a year for a premium package with a token allocation
    • Restricted to academic and research use, not work supporting a commercial enterprise
    • Maestro generally unrestricted with tokens shared for compute heavy applications

Which should you pick?

Choose Greenphire if

  • You need clincard.
  • You work on Web, iOS, Android.
  • You also want direct to bank payment.
Greenphire review

Choose Schrodinger if

  • You need maestro.
  • You work on Linux, macOS, Windows, Web.
  • You also want glide.
Schrodinger review

Questions people ask

Is Greenphire or Schrodinger better?
Neither clearly leads. Greenphire starts at On request and Schrodinger at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Greenphire or Schrodinger?
Greenphire starts at On request and Schrodinger at On request.
Does Greenphire or Schrodinger run on more platforms?
Greenphire runs on Web, iOS, Android. Schrodinger runs on Linux, macOS, Windows, Web.
What is Greenphire best used for?
Greenphire is most often used for a global phase iii trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payable, a decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodation, a trial in a population where slow reimbursement drives dropout and same day payment materially helps retention, a sponsor that wants site payment milestones and participant payments handled by one vendor rather than two. Of those, a global phase iii trial paying stipends across many countries where participants cannot practically be reimbursed by sponsor accounts payable and a decentralised or hybrid trial where participants travel long distances and the sponsor funds flights and accommodation are not what Schrodinger is typically brought in for.
What can Greenphire do that Schrodinger cannot?
Greenphire covers ClinCard, Direct to bank payment, Expense reimbursement, Travel and logistics. Schrodinger covers Maestro, Glide, FEP+, Desmond.

Answered from the vendors’ own pages

Greenphire: Is Greenphire still sold?

Yes, as Greenphire Patient Payments on the Suvoda platform. The independent website and social presence have been consolidated into Suvoda.

Schrodinger: How is Schrodinger software licensed?

Annual licences with a shared token pool. Tokens cap how much you can run at once rather than which modules you own outright.

Greenphire: What is ClinCard?

The reloadable debit card Greenphire issues to participants. Greenphire Patient Payments was formerly known as ClinCard.

Schrodinger: Is there published pricing?

Only for academic site licences, which start around 7,500 USD a year for a premium package. Commercial pricing is quoted.

Greenphire: Does it publish pricing?

No. Pricing is per study and quoted through sales, and funding the payments themselves is separate from the software fee.

Schrodinger: Do I need my own GPUs?

For FEP+ and Desmond in practice yes, or cloud GPU capacity. Compute is not included in the licence.

Greenphire: Can it pay participants outside the United States?

Yes, in more than thirty currencies, but the available payment method depends on the country.

Schrodinger: Does Schrodinger compete with its customers?

It runs its own drug pipeline as well as selling software. It manages this through contractual separation, but buyers with sensitive targets should raise it during procurement.

Share

Related pages

More on Greenphire

More on Schrodinger

Keep looking

Other head to heads